Cluster of Excellence –
University of Freiburg

PD Dr. Bernd Kammerer

PD Dr. Bernd Kammerer

Core Facility Metabolomics, ZBSA, University of Freiburg

+49 761 203 97137

Research Interests:

  • Regulation of plant biochemical pathways to investigate central metabolism, biosynthesis of secondary metabolites, signalling and stress response
  • Biosynthesis and analysis of secondary metabolites from different bacterial strains as new therapeutic agents by „combinatorial biosynthesis”
  • Metabolomics to unravel molecular mechanisms involved in Parkinson's disease
  • Biomarker identification in breast cancer
  • Metabolomics Changes in Ciliopathy: The role of the nephronophthisis Anks6 module in development and tissue homeostasis
  • Analysis of the mitochondrial metabolome smORF gene mutants in yeast
  • Metabolomic signatures of aggressive prostate cancer

 

10 selected publications

  • Exometabolom analysis of breast cancer cell lines: Metabolic signature.
    Willmann L, Erbes T, Halbach S, Brummer T, Jäger M, Hirschfeld M, Fehm T, Neubauer H, Stickeler E, Kammerer B.
    Sci Rep. 2015 Aug 21;5:13374.
  • Metabolome analysis via comprehensive two-dimensional liquid chromatography: identification of modified nucleosides from RNA metabolism.
    Willmann L, Erbes T, Krieger S, Trafkowski J, Rodamer M, Kammerer B.
    Anal Bioanal Chem. 2015 May;407(13):3555-66
  • Metabolomic changes in Caenorhabditis elegans lifespan mutants as evident from GC–EI–MS and GC–APCI–TOF–MS profiling.
    Jaeger C, Tellström V, Zurek G, König G, Eimer S, Kammerer B.
    Metabolomics 2014;10(5), 859-876.
  • Hedgehog partial agonism drives Warburg-like metabolism in muscle and brown fat.
    Teperino R, Amann S, Bayer M, McGee SL, Loipetzberger A, Connor T, Jaeger C, Kammerer B, Winter L, Wiche G, Dalgaard K, Selvaraj M, Gaster M, Lee-Young RS, Febbraio MA, Knauf C, Cani PD, Aberger F, Penninger JM, Pospisilik JA, Esterbauer H.
    Cell. 2012 Oct 12;151(2):414-26
  • Reversal of P-glycoprotein-mediated multidrug resistance by the murine double minute 2 antagonist nutlin-3.
    Michaelis M, Rothweiler F, Klassert D, von Deimling A, Weber K, Fehse B, Kammerer B, Doerr HW, Cinatl J Jr.
    Cancer Res. 2009 Jan 15;69(2):416-21.
  • Metabonomics in cancer diagnosis: mass spectrometry-based profiling of urinary nucleosides from breast cancer patients.
    Frickenschmidt A, Frohlich H, Bullinger D, Zell A, Laufer S, Gleiter CH, Liebich H, Kammerer B.
    Biomarkers. 2008 Jun;13(4):435-49
  • Metabolic signature of breast cancer cell line MCF-7: profiling of modified nucleosides via LC-IT MS coupling.
    Bullinger D, Neubauer H, Fehm T, Laufer S, Gleiter CH, Kammerer B.
    BMC Biochem. 2007 Nov 29;8:25.
  • In vitro metabolite identification of ML3403, a 4-pyridinylimidazole-type p38 MAP kinase inhibitor by LC-Qq-TOF-MS and LC-SPE-cryo-NMR/MS
    Kammerer B, Scheible H, Zurek G, Godejohann M, Zeller KP, Gleiter CH, Albrecht W, Laufer S.
    Xenobiotica 2007;37(3), 280-297.
  • MALDI-TOF MS analysis of urinary nucleosides.
    Kammerer B, Frickenschmidt A, Gleiter CH, Laufer S, Liebich H.
    J Am Soc Mass Spectrom. 2005 Jun;16(6):940-7
  • Mass spectrometric identification of modified urinary nucleosides used as potential biomedical markers by LC-ITMS coupling.
    Kammerer B, Frickenschmidt A, Müller CE, Laufer S, Gleiter CH, Liebich H.
    Anal Bioanal Chem. 2005 Jun;382(4):1017-26.